|
Paul Carter joined Seattle Genetics in February 2003. Prior to joining the company, Dr. Carter was with Amgen Inc., where he was Director of Research, Antibody Technologies since Amgen's acquisition of Immunex Corporation in July 2002. He joined Immunex in September 2000, where he was the founding director of the protein engineering department with a focus on engineering human antibodies and other proteins for therapy. Previously, Dr. Carter was with Genentech, Inc. for 14 years. While at Genentech, he initiated the company's antibody humanization program and humanized three antibodies, including the Herceptin� anti-HER2/neu antibody that was approved by the FDA for the treatment of metastatic breast cancer over-expressing HER2. Dr. Carter received a B.A. in Natural Sciences from Cambridge University in 1982 and a Ph.D. in 1986 under Dr. Greg Winter at the MRC Laboratory of Molecular Biology in Cambridge. He has authored more than 85 scientific publications and is an inventor on over 35 U.S. patents and patent applications.
| 